BioAge Labs BIOA
NASDAQ BIOA
$5.52 -0.04 (-0.72%)
As of: Oct 21, 2026 · 3:59 PM EDT

BioAge Labs (BIOA) EBITDA Margin (2025 - 2026)

Updated

BioAge Labs (BIOA) recorded EBITDA Margin of -1193.92% in Q2 2026, down 169.54 percentage points from -1024.38% a year earlier and down 280.79 percentage points from the prior quarter.

Analysis

BioAge Labs (BIOA) EBITDA Margin (2025 - 2026) Analysis & Trends

On a TTM basis, BioAge Labs' EBITDA Margin came in at -1023.90% as of Jun 30, 2026, up 1334.65 percentage points year-over-year; for FY2025, it was -1029.09%.

  • Per Business Quant, the preceding three quarters came in at -913.13% (Q1 2026), -921.18% (Q4 2025) and -1124.44% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 BioAge Labs 245.72 Mn -1.55 Bn -14.23 Mn -1,193.92%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,193.92%
Mar 31, 2026 -913.13%
Dec 31, 2025 -921.18%
Sep 30, 2025 -1,124.44%
Jun 30, 2025 -1,024.38%
Mar 31, 2025 -1,130.88%
API Access

BioAge Labs EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=BIOA&period=max&api_key=YOUR_API_KEY